• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Edgewise

Edgewise Therapeutics

A Movement in Muscle

  • Clinical Trials
  • Careers
  • Investors & News
  • Company
    • Company Overview
    • Leadership Team
    • Careers
    • Contact Us

    We are dedicated to transforming cardiovascular muscle diseases.

    Learn More

  • Science
    • Pipeline
    • EDG-7500
    • EDG-15400
    • Clinical Trials
    • Posters & Presentations

    All of us at Edgewise are committed to developing new medicines for people facing serious cardiovascular diseases with unmet medical needs.

    Explore our Pipeline

  • Disease Areas
    • Cardiovascular Diseases
    • Muscular Dystrophy & Sevasemten

    Servier Acquires Our Muscular Dystrophy Program

    Following the close of our transaction with Servier, Edgewise’s muscular dystrophy business, including sevasemten, is now part of Servier. Servier’s global capabilities and commitment to neuromuscular diseases position it to advance sevasemten and continue supporting the patient and advocacy communities we have been privileged to serve.

    Edgewise is now focused exclusively on advancing high-impact therapies for people living with serious cardiovascular diseases.

    Learn more

  • Patients & Families
  • Investors & News
    • Corporate Profile
    • News
    • Events & Presentations
    • Analyst Coverage
    • Stock Info
      • Stock Quote
      • Stock Chart
      • Historical Stock Quote
      • Investment Calculator
    • Financials
      • Quarterly Results
      • SEC Filings
    • Governance
      • Governance Documents
      • Committee Composition
    • Resources
      • Investor FAQs
      • Investor Email Alerts
      • Investor Contacts
Home Company Leadership Team John Moore

John Moore

General Counsel

John Moore has served as our General Counsel since September 2020. He has many years of experience as General Counsel for small molecule biopharmaceutical companies working in a range of therapeutic areas. Mr. Moore was most recently General Counsel and Secretary at Peloton Therapeutics, where he led the legal aspects of the company’s initial public offering efforts and advised on its acquisition by Merck on the eve of its planned IPO. Prior to Peloton, Mr. Moore served for 15 years as General Counsel and Secretary at Array BioPharma, Inc. and for 5 years on the board of directors of Nivalis Therapeutics. Prior to Array, he was an attorney in private practice with Wilson Sonsini. Mr. Moore holds a B.S. in chemistry from the University of North Carolina, an M.S. in biochemistry from the University of Illinois and a J.D. from the University of North Carolina.

  • Meet our leadership team
  • Meet our board of directors

Footer

Edgewise Therapeutics
  • Company
  • Science
  • Disease Areas
  • Patients & Families
  • Investors & News

In the Clinic

We are advancing novel precision therapeutics for serious cardiovascular disease.

Explore our pipeline

2026 © Copyright. Edgewise Therapeutics. All Rights Reserved.

  • Privacy Policy
  • Terms of Use
Facebook X, formally Twitter LinkedIn Instagram YouTube
logo
  • Company
    • Leadership Team
    • Careers
    • Contact Us
  • Science
    • Pipeline
    • EDG-7500
    • EDG-15400
    • Clinical Trials
    • Posters & Presentations
  • Disease Areas
    • Cardiovascular Diseases
    • Muscular Dystrophy & Sevasemten
  • Patients & Families
  • Investors & Media
    • Corporate Profile
    • News
    • Events & Presentations
    • Analyst Coverage
    • Stock Info
      • Stock Quote
      • Stock Chart
      • Historical Stock Quote
      • Investment Calculator
    • Financials
      • Quarterly Results
      • SEC Filings
    • Goverance
      • Governance Documents
      • Committee Composition
    • Resources
      • Investor FAQs
      • Investor Email Alerts
      • Investor Contacts